Rakhi Thalayattu Vidhyadharan

Medicine · Health Sciences

2h-index16citations11works0.72yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(8), Retinoids in leukemia and cellular processes(6), Chronic Myeloid Leukemia Treatments(5), Protein Degradation and Inhibitors(3), Genomics, phytochemicals, and oxidative stress(2)

Publications11 total

POSTER: AML-927 RXRA Ligand and FLT3 Inhibitor Combination Shows Synergistic Effect in FLT3-ITD–Mutated Acute Myeloid Leukemia
Clinical Lymphoma Myeloma & Leukemia·2025
AML-927: RXRA Ligand and FLT3 Inhibitor Combination Shows Synergistic Effect in FLT3-ITD–Mutated Acute Myeloid Leukemia
Clinical Lymphoma Myeloma & Leukemia·2025
3088 – RETINOIC ACID MIMETIC MEBENDAZOLE INDUCES RXRA TO ELICIT POTENT ANTI-LEUKEMIC EFFECT IN AML CELLS
Experimental Hematology·2024
3190 – RXRA MEDIATED REVERSAL OF IMATINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA – A TRANSCRIPTOMIC PROFILING STUDY
Experimental Hematology·2024
Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia
Annals of Hematology·2024· 2 cited
Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSCs) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs
Cellular Signalling·2024· 2 cited
Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo
Frontiers in Pharmacology·2023· 5 citedOpen Access
Corrigendum to “Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines” [Leukemia Res. 128, 107054]
Leukemia Research·2023
Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines
Leukemia Research·2023· 7 cited
Abstract 3977: Pharmacological inhibition of Nrf2 overcomes acquired resistance to arsenic trioxide in FLT3 mutated acute myeloid leukemia
Cancer Research·2022
Abstract 3973: Transcriptomic profiling of <i>in-vitro</i> modelled drug resistant AML cell lines unravel metabolic and stemness gene signatures
Cancer Research·2022

Frequent Co-authors

Raveen Stephen Stallon Illangeswaran(11), Poonkuzhali Balasubramanian(11), Bharathi M. Rajamani(10), Shaji R Velayudhan(10), Vikram Mathews(9), Daniel Zechariah Paul Jebanesan(7), Kezia Kanimozhi Sivakumar(3), Esther Sathya Bama Benjamin(3), Balaji Balakrishnan(3), Saswati Das(3), Arnab Maity(3), Nancy Beryl Janet(2), Ernest David(2), Ajith Mohan(2), Aby Abraham(2), Nayanthara Bijukumar(2), Rachel Mariam Renji(2), Uday Kulkarni(2), Aswin Anand Pai(1), Sreeja Karathedath(1)